We Believe
in the value of the individual, and the sanctity and dignity of life
We Research New Ideas
We Collaborate with Innovators
We Believe in Radical Thinking
We Are Discoverers:
Do not go where the path may lead; go instead where there is no path and leave a trail
We Test Our Theories with Peer Review
We Validate Our Results
Our Primary Question is Always: Will it Benefit Patients
We Will Provide Hope
We Will Pursue Novel Options
We Will Innovate Personalized Therapies
We Will Not Give Up, But Honor Patient’s Wishes
We Establish Practices Based Upon Patients’ Best Interests
We Value the Input of Our Staff
We Strive to Teach and Equip Our Staff
We Give Our Team Recognition for Their Efforts
We Transfer Ownership of Objectives to Our Team
We Believe Our Employees are Our Most Valuable Asset
We Allow Our Supporters to Realize Our Impact
We Transfer Our Vision to Those Who Support Our Mission
We Encourage Our Supporters to Communicate and Share Our Mission with Others
We Believe in Servant Leadership: Others Before Ourselves
We Drive Our Decisions Through the Lens of Individual Impact
We Believe in Careful Stewardship of Our Resources, and Patient-Centric Decisions
Our Founder
Mary C. Crowley impacted the lives of thousands through the wisdom and guidance she shared. Her life’s mission was to honor God by blessing and serving others.
Mary was born in 1915 in Missouri. She overcame tremendous obstacles as a young mother by moving to Dallas during the Great Depression with her two small children, Don and Ruth.
Determined to create a better life for herself and her family, Mary spent her days working and her evenings attending classes at Southern Methodist University. With her incredible vision, leadership qualities, and sheer tenacity, Mary started Home Interiors and Gifts in 1957, which grew to become a multi-million-dollar corporation.
History of Mary Crowley Cancer Research
Mary C. Crowley established Mary Crowley Cancer Research in 1997. The center began in downtown Dallas and expanded to ten locations throughout the U.S. Today, the research center operates on the Medical City campus in north Dallas. It consistently follows FDA guidelines and has tested investigational therapies from more than 300 pharmaceutical companies, serving patients from the U.S. and multiple countries.
Dedicated to Bringing Hope
Minal Barve, MD
Chief Medical Officer
James Strauss, MD
Clinical Scientific Director
Douglas W. Orr, MD
Physician Investigator
Reva Schneider, MD
Physician Investigator
Gilberto Jimenez-Justiniano, MD
Physician Investigator
Robert Mennel, MD
Physician Investigator
Leah Plato, PA-C, MPH, CCRP
Associate Director of Clinical & Scientific Operations
Ntombizodwa “Zodwa“ Sayi, MSN, RN, AGPCNP-BC
Nurse Practitioner
Jenifer Mallow
Nurse Practitioner
Jennifer Fox, MBA
Chief Executive Officer & Board Member
Minal Barve, MD
Chief Medical Officer
Deborah Montonen, CFRE
Vice President and Chief Development Officer
Stacy Meador
Vice President of Finance
Natalie Settele
VP of Clinical Research Operations
Jennifer Matson Hunter
Director of Research Operations
Roy W. Lamkin
Chair Of The Board
Scott Bradley Burris, MD
Vice Chair Of the Board
Adil Adi
Board Member
Vincent Bush
Board Member
Ron Carter
Board Member
Edwin Flores
Board Member
Jennifer Fox, MBA
Chief Executive Officer & Board Member
Tom Hulsey
Board Member
Thomas B. Hoyt
Board Member
Michael Kearins
Board Member
Edward W. Marx
Board Member
Rodney G. Olsen
Board Member
Mary Elizabeth Warner
Board Member
An Accelerated Approach to Cancer Research
Mary Crowley Cancer Research has conducted 800+ clinical trials for 7700+ patients in collaboration with 350+ different pharmaceutical partners. With our dedicated referral and consult team and outpatient/ inpatient hospital support, our site is designed, equipped, and staffed for conducting early phase solid tumor and hematology trials. Including performing 129 first-in-human trials, MCCR has completed phase I and phase II, industry funded studies such as first-in-human, drug-drug interaction, food effect, bioequivalence, and intensive EKG monitoring studies. This site has experience using gene therapies, cytokines, cytotoxic agents, cellular therapies, small molecules, viral therapies, monoclonal antibodies, antibody drug conjugates, immune therapy, and vaccines.
Study Start-Up
- 10 weeks from receipt of final protocol – may be shorter under our Just-in-Time (JIT) program
- Parallel completion of all startup activities
- Prompt review/approval – local Institutional Review Board meets weekly
Welcome to Our Clinic
The Administrative Offices
- 16,000 square foot administrative office space
- Dedicated research employees (Finance, Legal, Project Management, Regulatory, IRB, Development/Marketing/Business Development, Leadership)
- Monitoring suites with high-speed internet access
Our Accomplishments
See reports to our current and future donors that provides an overview of our accomplishments and how our funds are spent.
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.
7777 Forest Lane,
Building C-707
Dallas, TX 75230
972.566.3000